Zobrazeno 1 - 10
of 226
pro vyhledávání: '"B. Lacoste"'
Autor:
M. Tortarolo, B. Lacoste, J. Hem, C. Dieudonné, M.-C. Cyrille, J. A. Katine, D. Mauri, A. Zeltser, L. D. Buda-Prejbeanu, U. Ebels
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-7 (2018)
Abstract Integration of Spin Torque Nano-Oscillators STNO’s in conventional microwave circuits means that the devices have to meet certain specifications. One of the most important criteria is the phase noise, being the key parameter to evaluate th
Externí odkaz:
https://doaj.org/article/9393ceacf4864415b0b6f12b34308936
Autor:
J. D. Costa, S. Serrano-Guisan, B. Lacoste, A. S. Jenkins, T. Böhnert, M. Tarequzzaman, J. Borme, F. L. Deepak, E. Paz, J. Ventura, R. Ferreira, P. P. Freitas
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Reported steady-state microwave emission in magnetic tunnel junction (MTJ)-based spin transfer torque nano-oscillators (STNOs) relies mostly on very thin insulating barriers [resulting in a resistance × area product (R × A) of ~1 Ωμm2] t
Externí odkaz:
https://doaj.org/article/9267ca09d5b5472ea7782ac1f973d082
Electronic health records (EHRs) represent a rich data source to support precision medicine, particularly in disorders with small and heterogeneous populations where longitudinal phenotypes are poorly characterized. However, the impact of EHR data is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a27ef0076f572a985c98606a0fde9a92
https://doi.org/10.1101/2023.03.02.23286645
https://doi.org/10.1101/2023.03.02.23286645
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Scott Spangler, Sharon Hensley Alford, Lorraine V. Kalia, Italo Buleje, Piyush Madan, Alix M. B. Lacoste, Connie Marras, Yanyan Han, Naomi P. Visanji
Publikováno v:
Pharmacoepidemiology and Drug Safety. 30:201-209
PURPOSE Drug repurposing is an effective means of increasing treatment options for diseases, however identifying candidate molecules for the indication of interest from the thousands of approved drugs is challenging. We have performed a computational
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-19 (2020)
Scientific Reports
Scientific Reports
Incorrect drug target identification is a major obstacle in drug discovery. Only 15% of drugs advance from Phase II to approval, with ineffective targets accounting for over 50% of these failures1–3. Advances in data fusion and computational modeli
Autor:
Laura Ferraiuolo, Joanna D. Holbrook, Richard J. Mead, Poojitha N. Ojamies, Guillaume M. Hautbergue, Alix M. B. Lacoste, Amir Saffari, Monika A Myszczynska, Daniel Neil
Publikováno v:
Nature Reviews Neurology. 16:440-456
Globally, there is a huge unmet need for effective treatments for neurodegenerative diseases. The complexity of the molecular mechanisms underlying neuronal degeneration and the heterogeneity of the patient population present massive challenges to th
Autor:
Laura C. Maclagan, Naomi P. Visanji, Connie Marras, Lorraine V. Kalia, Susan E. Bronskill, Yi Cheng, Mina Tadrous, Alix M. B. Lacoste
Publikováno v:
Pharmacoepidemiology and Drug Safety. 29:864-872
Purpose The aim of the study was to assess the feasibility of an approach combining computational methods and pharmacoepidemiology to identify potentially disease-modifying drugs in Parkinson's disease (PD). Methods We used a two-step approach; (a) c
Autor:
Suneil K. Kalia, Omar M. A. El-Agnaf, Jarlath Byrne Rodgers, Aldis Krizus, Minesh Kapadia, Darren M O'Hara, Kazuko Fujisawa, Lorraine V. Kalia, Krystal Menezes, Joseph G. Culotti, Kevin S Chen, William S. Ryu, Susan Ping, Naomi P. Visanji, Hien Chau, Grishma Pawar, Satoshi Suo, Nour K. Majbour, Seiya Ishikura, Andres M. Lozano, Scott Spangler, Nhat Tran, Anna Cranston, Alix M. B. Lacoste, Shahin Khodaei, Connie Marras
Publikováno v:
Molecular Neurodegeneration
Molecular Neurodegeneration, Vol 16, Iss 1, Pp 1-25 (2021)
Molecular Neurodegeneration, Vol 16, Iss 1, Pp 1-25 (2021)
Background Parkinson’s disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by α-synuclein oligomers. There is an urgent need for disease-modifying therapies for Parkinson’s disease, but dr
Autor:
Daniel P. Smith, Ed Savory, Olly Oechsle, Alix M. B. Lacoste, Peter John Richardson, Michael J. Rawling
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology, Vol 12 (2021)
The onset of the 2019 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic necessitated the identification of approved drugs to treat the disease, before the development, approval and widespread administration of suitable vaccines. T